2-氯-6-氟苯肼 | 175276-74-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-6-氟苯肼
• 中文别名: 1-(2-氯-6-氟苯基)肼
• 英文名称: (2-chloro-6-fluoro-phenyl)hydrazine
• 英文别名: 2-Chloro-6-fluorophenylhydrazine；(2-chloro-6-fluorophenyl)hydrazine
• CAS: 175276-74-1
• 化学式: C₆H₆ClFN₂
• 分子量: 160.578
• InChiKey: CGMWMYHEKGCISN-UHFFFAOYSA-N

物化性质

• 熔点：
  67-69°C
• 沸点：
  210℃
• 密度：
  1.430
• 闪点：
  81℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R20/21/22
• 海关编码：
  2928000090
• 安全说明：
  S24/25,S36/37/39

反应信息

• 作为反应物：
  描述：

  2-氯-6-氟苯肼 在 N-碘代丁二酰亚胺 、 XPhos Pd G2 、 三甲基铝 、 sodium carbonate 、 溶剂黄146 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 氯苯 为溶剂， 生成 (R)-2-(2-chloro-6-fluorophenyl)-1-(2-hydroxypropyl)-5-methyl-4-phenyl-1H-pyrazol-3(2H)-one
  参考文献：
  名称：

  19F NMR spectroscopy as a tool to detect rotations in fluorine substituted phenyl compounds

  摘要：

  Atropisomerism becomes a popular structural feature in modern drug discovery. Using N-phenyl gamma-lactam and phenyl-pyrazolone scaffolds, we showed that distinct F-19 NMR peaks were present in atropisomers and dual signals emerged for covalently identical fluorine nuclei in hindered rotamers. Factors affecting F-19 NMR chemical shifts in these molecules were discussed. We demonstrated that F-19 NMR spectroscopy can be used to differentiate and detect atropisomers and rotamers in conformationally restricted molecules. (C) 2020 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2020.131679

文献信息

• [EN] SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE TRIAZOLE SUBSTITUÉS ET UTILISATIONS ASSOCIÉES
  申请人：BAYER PHARMA AG

  公开号：WO2019081302A1

  公开（公告）日：2019-05-02

  The present invention relates to novel substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.

  本发明涉及新型的取代1,2,4-三唑衍生物，这些化合物的制备方法，包含这些化合物的药物组合物，以及这些化合物或组合物用于治疗和/或预防疾病的使用，特别用于治疗和/或预防肾脏和心血管疾病。
• Hydrazide and alkoxyamide angiogenesis inhibitors
  申请人：——

  公开号：US20020002152A1

  公开（公告）日：2002-01-03

  Compounds having the formula 1 are methionine aminopeptidase type 2 (MetAP2) inhibitors and are useful for inhibiting angiogenesis. Also disclosed are MetAP2-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.

  具有以下化学式的化合物是蛋氨酸氨肽酶2型（MetAP2）抑制剂，对抑制血管生成有用。还公开了抑制MetAP2的组合物和在哺乳动物中抑制血管生成的方法。
• [EN] DIHYDROOROTATE DEHYDROGENASE INHIBITORS<br/>[FR] INHIBITEURS DE DIHYDROOROTATE DÉSHYDROGÉNASE
  申请人：JANSSEN BIOTECH INC

  公开号：WO2020212897A1

  公开（公告）日：2020-10-22

  Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, X, and Y are defined herein.

  揭示了一种通过调节DHODH来治疗受影响的疾病、紊乱或医疗状况的化合物、组合物和方法。这些化合物由以下式（I）所代表：其中R1、R2、R3、R4、X和Y在此处定义。
• IMIDAZO[1,2-b]PYRIMIDO[4,5-d]PYRIDAZIN-5(6H)-ONES AND THE USE THEREOF
  申请人：IMPACT THERAPEUTICS, INC.

  公开号：US20200131192A1

  公开（公告）日：2020-04-30

  Disclosed are imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R 1 -R 5 are defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.

  本文揭示了咪唑[1,2-b]嘧啶并[4,5-d]吡啶嗪-5(6H)-酮化合物，具体由公式I表示：或其药用可接受的盐或前药，其中A和R1-R5在此定义。具有公式I的化合物是Wee1激酶抑制剂。因此，本公开的化合物可用于治疗由异常Wee1活性引起的疾病。
• [EN] PYRIDAZINO [4, 5 -D] PYRIMIDIN- (6H) -ONE INHIBITORS OF WEE - 1 KINASE<br/>[FR] INHIBITEURS DE KINASE WEE-1 DE TYPE PYRIDAZINO[4,5-D]PYRIMIDIN-(6H)ONE
  申请人：ABBVIE INC

  公开号：WO2013013031A1

  公开（公告）日：2013-01-24

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, Formula (I) wherein B, R1, R2, R4, and m are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.

  本发明涉及公式(I)化合物或其药学上可接受的盐，公式(I)中B、R1、R2、R4和m的定义见说明书。本发明还涉及含有上述化合物的组合物，其对抑制wee-1等激酶有用，并且用于治疗癌症等疾病的方法。